Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of izokibep in ankylosing spondylitis
CTR20212210Phase 2Suspended
- Sponsor
- Affibody Medical AB
- Start
- Mar 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of izokibep in ankylosing spondylitis (AS), sponsored by Affibody Medical AB. Started Mar 2022; status: suspended.
02
Drugs
izokibep
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20212210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212210.